Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 13;27(148):180004.
doi: 10.1183/16000617.0004-2018. Print 2018 Jun 30.

Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era

Laurent Savale  1   2   3 , Christophe Guignabert  1   3 , Jason Weatherald  4   5 , Marc Humbert  1   2   3
Affiliations
Review

Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era

Laurent Savale et al. Eur Respir Rev. .

Abstract

Pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) include different cardiopulmonary disorders in which the interaction of multiple genes with environmental and behavioural factors modulates the onset and the progression of these severe conditions. Although the development of therapeutic agents that modulate abnormalities in three major pathobiological pathways for PAH has revolutionised our approach to the treatment of PAH, the long-term survival rate remains unsatisfactory. Accumulating evidence has underlined that clinical outcomes and responses to therapy in PAH are modified by multiple factors, including genetic variations, which will be different for each individual. Since precision medicine, also known as stratified medicine or personalised medicine, aims to better target intervention to the individual while maximising benefit and minimising harm, it has significant potential advantages. This article aims to assemble and discuss the different initiatives that are currently underway in the PH/PAH fields together with the opportunities and prospects for their use in the near future.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: L. Savale reports grants and personal fees from Actelion and Bayer, and personal fees from MSD and GSK, during the conduct of the study. Conflict of interest: J. Weatherald reports grants from the European Respiratory Society and the Canadian Thoracic Society, as well as personal fees and non-financial support from Actelion and Bayer, outside the submitted work. Conflict of interest: M. Humbert reports personal fees from Actelion Pharmaceuticals Ltd, United Therapeutics and Pfizer, and grants and personal fees from Bayer, during the conduct of the study. He has received personal fees from Novartis, outside the submitted work. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards.

Figures

FIGURE 1
FIGURE 1
New “-omics” approach for personalised medicine. PAH: pulmonary arterial hypertension. Reproduced and modified from [3] with permission.
See this image and copyright information in PMC

Comment in

  • doi: 10.1183/16000617.0088-2017

References

    1. Simonneau G, Gatzoulis MA, Adatia I, et al. . Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013; 62: 25 Suppl, D34–D41. - PubMed
    1. Galie N, Humbert M, Vachiery J-L, et al. . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J 2015; 46: 903-975. - PubMed
    1. Austin ED, West J, Loyd JE, et al. . Translational advances in the field of pulmonary hypertension molecular medicine of pulmonary arterial hypertension. From population genetics to precision medicine and gene editing. Am J Respir Crit Care Med 2017; 195: 23–31. - PMC - PubMed
    1. Benza RL, Miller DP, Barst RJ, et al. . An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012; 142: 448–456. - PubMed
    1. Guignabert C, Tu L, Le Hiress M, et al. . Pathogenesis of pulmonary arterial hypertension: lessons from cancer. Eur Respir Rev 2013; 22: 543–551. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources